Core Viewpoint - RBC Capital initiated coverage on Bicycle Therapeutics PLC (BCYC), highlighting its competitive edge in oncology, particularly with its lead program Zelenectide pevedotin (zele) in metastatic urothelial cancer (mUC) [1][2] Group 1: Product and Market Potential - Zelenectide shows potential to compete with Pfizer's Padcev in mUC, demonstrating similar objective response rates and fewer adverse events [1] - The improved safety profile of Zelenectide could lead to greater antitumor durability, distinguishing it from Padcev [1] - The analyst estimates Zelenectide could achieve peak global sales of approximately $2 billion by 2033 [1] - Commercialization opportunities in non-mUC indications are expected to be less competitive, providing additional upside for Zelenectide [1] Group 2: Regulatory and Clinical Insights - The regulatory path for Zelenectide is considered de-risked following FDA alignment on the Duravelo-2 trial [2] - Strong demand for a safer Nectin-4 drug conjugate is indicated by RBC's proprietary oncologist survey [2] - Zelenectide has potential therapeutic applications in additional solid tumor indications, including triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), which are not addressed by Padcev [2] Group 3: Financial Position and Future Prospects - Bicycle Therapeutics has generated over $200 million in non-dilutive capital through its internal pipeline and external partnerships [3] - Future value creation is anticipated from next-generation Bicycle Toxin Conjugates (BTCs), radiopharmaceutical applications, and expansion beyond oncology [3] - As of June 30, 2024, the company reported cash and cash equivalents of $961.4 million, expected to sustain operations into the second half of 2027 [3] Group 4: Stock Performance - BCYC stock experienced a 1.27% increase, reaching $20.69 in the latest trading session [3]

Company Overview - Bicycle Therapeutics was founded by Nobel laureate Dr. Greg Winter, known for his work on humanizing monoclonal antibodies, which initiated the mAb revolution in medicine [3] - The company's core technology, "bicycles," are small protein structures that offer advantages over monoclonal antibodies, including size, stability, and production efficiency [3] - Bicycles are smaller (9 to 20 amino acids) compared to mAbs (1200 to 1500 amino acids), leading to improved stability and faster tissue penetration [3] - Bicycles are recognized as small molecule new chemical entities by regulatory authorities, resulting in lower production costs and a broader target spectrum [3] Pipeline - BCYC's lead internal program, BT8009, is a bicycle toxin conjugate targeting tumors overexpressing Nectin-4, currently in phase 1/2 and phase 2/3 trials [4][5] - Other internal programs include BT5528, targeting EphA2, and BT7480, targeting Nectin-4/CD137, both in phase 1/2 trials [4][5] - A partnered program, BT1718, is targeting high MT1-MMP expressing tumors in collaboration with Cancer Research UK [5] Clinical Data - BT8009 demonstrated a 38% objective response rate (ORR) in a phase 1/2 trial among 26 patients with metastatic urothelial cancer, with a median duration of response of 11.1 months [6] - BT5528 achieved a 39% ORR among 18 patients with metastatic urothelial cancer, with a median duration of response of four months [7] - Both BT8009 and BT5528 exhibited a favorable safety profile, with low frequency and severity of treatment-related adverse events [7] Competitive Landscape - Bicycle Therapeutics operates in a novel therapeutic space with no direct competitors developing bicycles [8] - Competing molecules include PACDEV, an approved Nectin-4 targeting antibody drug conjugate by Pfizer, and MedImmune's MEDI-547 targeting EphA2 [8] Financials and Collaborations - BCYC has a market cap of $1.54 billion and a cash balance of $961 million, with a cash runway projected through 2027 [9] - The company holds over 344 patents and has collaborations with major pharmaceutical companies including Bayer, Genentech, and Novartis [10]

Investors might want to bet on Bicycle Therapeutics PLC Sponsored ADR (BCYC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and f ...

Bicycle Therapeutics PLC Sponsored ADR (BCYC) closed the last trading session at $22.96, gaining 3.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $43.38 indicates an 88.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $12.91. While the lowest estimate of $28 indicates a 22% increase from the current price level, the mos ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value £0.01 per share* n/a The Nasdaq Stock Market LLC American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ...

Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results Four abstracts containing data updates across clinical pipeline accepted for poster presentation at ESMO Congress 2024 Focused R&D pipeline on clinical programs and research areas that have the highest potential to maximize value creation Streamlined leadership team to better align with strategic and pipeline priorities, and enhanced oncology expertise with formation of Clinical Advisory Board Streng ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Bicycle Therapeutics PLC Sponsored ADR (BCYC) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bicycle Therapeutics PLC Sponsored ADR is one of 1040 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. ...

Group 1 - Bicycle Therapeutics PLC Sponsored ADR (BCYC) has gained approximately 28.1% year-to-date, outperforming the average gain of 6.2% in the Medical sector [2] - The Zacks Consensus Estimate for BCYC's full-year earnings has increased by 14.6% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [2] - BCYC is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [1] Group 2 - Bicycle Therapeutics PLC is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 3.8% year-to-date, highlighting BCYC's superior performance [3] - Another outperforming stock in the Medical sector is Brookdale Senior Living (BKD), which has returned 14.6% year-to-date and is also ranked 2 (Buy) [2] - The Medical - Nursing Homes industry, to which Brookdale Senior Living belongs, is currently ranked 16 and has gained 7.5% year-to-date [3]

Core Viewpoint - Bicycle Therapeutics (BCYC) has entered into a funding agreement to issue 25,933,706 American Depositary Shares (ADS) at $21.42 per share, expected to generate approximately $555 million in gross proceeds, significantly strengthening its cash position and extending its financial runway into the second half of 2027 [1][2]. Group 1: Funding and Financial Position - The PIPE financing will close on May 28, 2024, contingent upon customary closing conditions [1]. - Post-transaction, the company anticipates its cash and cash equivalents to be around $1 billion, which is an estimate subject to change [2]. - Net proceeds from the PIPE funding will support ongoing development activities of its clinical-stage pipeline [2]. Group 2: Clinical Pipeline and Development - Bicycle Therapeutics' lead candidate, BT8009, is being evaluated in two clinical studies for different cancer indications, including metastatic bladder cancer [2][3]. - The company has aligned with the FDA on the design of the Duravelo-2 study, which may lead to accelerated approval for treating metastatic bladder cancer [3]. - The clinical-stage pipeline includes three other candidates: BT5528, BT1718, and BT7480, which are in various stages of development [3]. Group 3: Market Performance - Year to date, BCYC shares have increased by 29.9%, contrasting with a 6% decline in the industry [2].

Core Viewpoint - Bicycle Therapeutics PLC (BCYC) shows significant upside potential with a mean price target of $43.56, indicating an 85.5% increase from its current price of $23.48 [1] Price Targets and Analyst Consensus - The mean estimate consists of nine short-term price targets with a standard deviation of $11.61, suggesting variability in analyst predictions [1] - The lowest estimate of $30 indicates a 27.8% increase, while the highest estimate suggests a 155.5% surge to $60 [1] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [4] Earnings Estimates and Revisions - Analysts have shown increasing optimism about BCYC's earnings prospects, with eight estimates revised higher in the last 30 days and no negative revisions [5] - The Zacks Consensus Estimate for the current year has increased by 14.6% due to these positive revisions [5] Zacks Rank and Investment Potential - BCYC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [6] - This rank, along with the positive earnings revisions, suggests a strong potential for upside in the near term [6]